8 results
Pain Assessment and Management Initiative (PAMI) - Neuropathic Pain Medications:

Agent, Initiation Dose and Max Dosages

 -
: Agent, Initiation ... Dose and Max Dosages ... Management #Pain #Pharmacology ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Non-Opioid Analgesics - Agents ... #Pain #Pharmacology ... NonOpioid #Analgesics #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Muscle Relaxants - Agents and Dosing

#Management #Pain #Pharmacology #Muscle
Muscle Relaxants - Agents ... #Pain #Pharmacology ... Relaxers #Relaxants #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Nerve Blocks - Nerve Distribution, Agents and Dosing Table
Distribution, Agents ... and Dosing Table ... Nerve #Blocks #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Intranasal and Nebulized Medications- Agents and Dosing

#Management #Pain #Pharmacology
Management Initiative (PAMI ... - Agents and Dosing ... Management #Pain #Pharmacology ... #Doses #Dosing ... #Table #PAMI
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Normal and Renal Dosing ... very tolerable medication ... #Pharmacology # ... Management #Diabetes #DM2 ... #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP ... Diabetes #Mellitus #DM2 ... #pharmacology # ... comparison #table ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... drug to remain stable ... empagliflozin and DPP4 ... semaglutide #Diabetes #Pharmacology ... #Endocrinology